MA45149A - Méthodes de traitement de la maladie d'alzheimer - Google Patents

Méthodes de traitement de la maladie d'alzheimer

Info

Publication number
MA45149A
MA45149A MA045149A MA45149A MA45149A MA 45149 A MA45149 A MA 45149A MA 045149 A MA045149 A MA 045149A MA 45149 A MA45149 A MA 45149A MA 45149 A MA45149 A MA 45149A
Authority
MA
Morocco
Prior art keywords
alzheimer
disease
treatment
methods
Prior art date
Application number
MA045149A
Other languages
English (en)
Inventor
Brendon Phillip Boot
Jeffrey Joseph Sevigny
Leslie Lugene Williams
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of MA45149A publication Critical patent/MA45149A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA045149A 2016-06-07 2017-06-06 Méthodes de traitement de la maladie d'alzheimer MA45149A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US201662435531P 2016-12-16 2016-12-16

Publications (1)

Publication Number Publication Date
MA45149A true MA45149A (fr) 2019-04-10

Family

ID=59067640

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045149A MA45149A (fr) 2016-06-07 2017-06-06 Méthodes de traitement de la maladie d'alzheimer

Country Status (12)

Country Link
US (2) US20200308259A1 (fr)
EP (1) EP3464350A1 (fr)
JP (3) JP2019517540A (fr)
KR (2) KR20230165883A (fr)
CN (3) CN114931635A (fr)
AU (2) AU2017276656A1 (fr)
BR (1) BR112018075300A2 (fr)
CA (1) CA3026598A1 (fr)
IL (1) IL263433B2 (fr)
MA (1) MA45149A (fr)
MX (1) MX2018015022A (fr)
WO (1) WO2017211827A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (fr) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Cible thérapeutique et anticorps monoclonaux contre elle pour le diagnostic et le traitement de la maladie d'alzheimer
WO2020193644A1 (fr) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
WO2021081101A1 (fr) * 2019-10-22 2021-04-29 Biogen Ma Inc. Anticorps anti-bêta-amyloïde pour traiter la maladie d'alzheimer
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
TW202313111A (zh) * 2021-06-07 2023-04-01 美商百健Ｍａ公司 治療阿茲海默症之方法
WO2023055733A1 (fr) * 2021-09-30 2023-04-06 The Scripps Research Institute Composés pour réduire la neuro-inflammation
IL312715A (en) * 2021-11-19 2024-07-01 Ap Biosciences Inc Bispecific Antibodies Directed to CD137 and Their Uses for Cancer Immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2468770T1 (en) * 2006-07-14 2018-05-31 Ac Immune S.A. A humanized antibody against amyloid beta.
EP2099826B1 (fr) 2007-01-05 2013-10-16 University Of Zurich Anticorps anti-amyloide et son utilisation
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
KR102308915B1 (ko) * 2012-10-15 2021-10-06 메디뮨 리미티드 아밀로이드 베타에 대한 항체
CN105979962A (zh) * 2012-12-07 2016-09-28 比奥根国际神经科学公司 使用抗Aβ抗体减少脑淀粉样蛋白斑块的方法
BR112015014751A8 (pt) 2012-12-21 2018-01-16 Biogen Int Neuroscience Gmbh anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
AU2015214058B2 (en) * 2014-02-08 2020-07-09 Genentech, Inc. Methods of treating Alzheimer's Disease
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
AU2024216442A1 (en) 2024-10-17
MX2018015022A (es) 2019-08-14
KR20230165883A (ko) 2023-12-05
JP2019517540A (ja) 2019-06-24
CA3026598A1 (fr) 2017-12-14
CN114931635A (zh) 2022-08-23
WO2017211827A1 (fr) 2017-12-14
IL263433B1 (en) 2023-11-01
US20200308259A1 (en) 2020-10-01
JP2025160337A (ja) 2025-10-22
JP2022145965A (ja) 2022-10-04
BR112018075300A2 (pt) 2019-04-30
IL263433B2 (en) 2024-03-01
CN114796481A (zh) 2022-07-29
EP3464350A1 (fr) 2019-04-10
US20220281963A1 (en) 2022-09-08
IL263433A (en) 2019-01-31
CN109476730A (zh) 2019-03-15
KR20190021311A (ko) 2019-03-05
AU2017276656A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
EP3645121A4 (fr) Méthodes de traitement de la maladie de huntington
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
EP3515505A4 (fr) Traitement vaa de la maladie de huntington
MA41115A (fr) Procédé de traitement de la maladie d'alzheimer
EP3458589A4 (fr) Compositions et méthodes de traitement de la maladie de huntington
EP3291815A4 (fr) Méthodes de traitement d'une maladie neurodégénérative
EP3490582A4 (fr) Méthodes et compositions de traitement de maladie.
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
EP3644996A4 (fr) Procédés de traitement de la maladie de huntington
EP3534907A4 (fr) Compositions et méthodes de traitement d'une maladie hépatique
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3294345A4 (fr) Formulations de tpp1 et méthodes de traitement de la maladie cln2
EP3019523A4 (fr) Méthodes permettant de traiter la maladie d'alzheimer et la maladie de huntington
EP3377118A4 (fr) Méthodes pour traiter la maladie d'alzheimer et des troubles associés
EP3402533A4 (fr) Méthodes et compositions pour le traitement d'une maladie neurologique
EP3386520A4 (fr) Méthodes de traitement d'une maladie ou d'un trouble oculaire
EP3846830A4 (fr) Méthodes et compositions pour le traitement de maladie musculo-squelettiques
MA53329A (fr) Méthodes de traitement de l'épilepsie
LT3463351T (lt) Parkinsono ligos gydymas
PL3347002T3 (pl) Leczenie choroby alzheimera w konkretnej populacji pacjentów
EP3393468A4 (fr) Méthodes pour le traitement d'une maladie immunodéficiente
EP3454793A4 (fr) Bobines de traitement d'anévrisme
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
EP3634422A4 (fr) Méthodes de traitement de la leucodystrophie
EP3546449A4 (fr) Dérivé de pipéridine -2,6-dicétone et traitement de la maladie de crohn